抄録
The present study was designed to examine the cost-effectiveness of Flomoxef (FMOX) and Cefmetazole (CMZ) in the prophylactic antibiotic therapy after colorectal cancer surgery. Fifty-eight patients (47 in the FMOX group and 11 in the CMZ group), who underwent surgery for colorectal cancer at the First Department of Surgery of our hospital, were investigated. There was no significant difference between the 2 groups regarding the mean treatment period, the prophylactic effect of infection, or in changes in the white blood cell count (WBC), C-reactive protein (CRP), and serum creatinine (Cr) during the treatment period. However, the mean cost of treatment was significantly higher in the FMOX group than in the CMZ group, thus suggesting that the prophylactic effect of CMZ may be more cost-effective. Further evaluations of pharmacotherapy based on cost effectiveness may thus become one of the important duties of hospital pharmacists in the future.
